Investors can speculate about the future of a stock by watching how its insiders buy and sell stocks. Heron Therapeutics Inc shares valued at $27,250 were purchased by Forbes William P on Nov 17 ’23. At $1.09 per share, Forbes William P acquired 25,000 shares. The insider’s holdings grew to 79,000 shares worth approximately $0.17 million following the completion of this transaction.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Also, Forbes William P purchased 50,000 shares, netting a total of over 46,995 in proceeds. Following the buying of shares at $0.94 each, the insider now holds 54,000 shares.
Before that, Collard Craig A had added 150,000 shares to its account. In a trade valued at $137,970, the Chief Executive Officer bought Heron Therapeutics Inc shares for $0.92 each. Upon closing the transaction, the insider’s holdings increased to 150,000 shares, worth approximately $0.39 million.
As published in their initiating research note from Rodman & Renshaw on June 13, 2024, Heron Therapeutics Inc [HRTX] has been a Buy and the price target has been revised to $7. Analysts at CapitalOne started covering the stock with ‘”an Overweight”‘ outlook in a report released in late April. As of March 13, 2024, Needham has reiterated its “Buy” rating for HRTX. Earlier on May 27, 2020, Guggenheim initiated its rating. Their recommendation was “a Buy” for HRTX stock.
Analyzing HRTX Stock Performance
During the last five days, there has been a surge of approximately 10.58%. Over the course of the year, Heron Therapeutics Inc shares have jumped approximately 22.94%. Shares of the company reached a 52-week high of $3.93 on 06/12/24 and a 52-week low of $1.66 on 01/02/24. A 50-day SMA is recorded $2.12, while a 200-day SMA reached $2.61. Nevertheless, trading volume fell to 2.34 million shares from 1.52 million shares the previous day.
Support And Resistance Levels for Heron Therapeutics Inc (HRTX)
According to the 24-hour chart, there is a support level at 2.00, which, if violated, would cause prices to drop to 1.90. In the upper region, resistance lies at 2.16. The next price resistance is at 2.24. RSI (Relative Strength Index) is 55.58 on the 14-day chart, showing neutral technical sentiment. Moving Average Convergence Divergence (MACD) is at 0.06, which suggests the price will decrease in the coming days. Percent R is at 16.42%, indicating bullish price movement. Stochastics %K at holding indicates that the stock is to be held.
